RATIONALE: The antipsychotic drug, olanzapine, often induces weight gain and glucose metabolism disturbances, which may result from feeding pattern abnormalities. OBJECTIVES: The objectives of the study were to examine the effects of a chronic olanzapine treatment on feeding patterns in the rat and to investigate a potential time-related association between feeding patterns and the appearance of glucose metabolism abnormalities and adiposity. METHODS: Male rats were treated with olanzapine (2 mg/kg/day), haloperidol (1 mg/kg/day) or a control solution (drugs mixed with the food). In experiment 1, treatments lasted 26 days and feeding patterns were measured on day 21. In experiment 2, treatments lasted for 46 days, and an oral glucose tolerance test (OGTT) was realised on day 31. At the end of both experiments, plasma parameters and body composition were analysed. RESULTS: In experiment 1, olanzapine-treated animals showed increased meal number, decreased ingestion rate, meal size and inter-meal interval, and no change in total food intake. Plasma glucose, OGTT and body composition were not altered. In experiment 2, after 31 days of treatment, fasting blood glucose was increased and OGTT indicated an insulin resistance. After 46 days of treatment, hyperglycaemia was aggravated (compared to 31 days), and adiposity was increased in olanzapine-treated animals. In both experiments, the haloperidol-treated rats did not differ from the control ones. CONCLUSION: Chronic olanzapine treatment produces changes in feeding patterns, in a way consistent with an increased incentive drive to eat. As a whole, the results raise the hypothesis that long-term alteration of feeding pattern by olanzapine may predispose to disturbances in the regulation of energy metabolism.
RATIONALE: The antipsychotic drug, olanzapine, often induces weight gain and glucose metabolism disturbances, which may result from feeding pattern abnormalities. OBJECTIVES: The objectives of the study were to examine the effects of a chronic olanzapine treatment on feeding patterns in the rat and to investigate a potential time-related association between feeding patterns and the appearance of glucose metabolism abnormalities and adiposity. METHODS: Male rats were treated with olanzapine (2 mg/kg/day), haloperidol (1 mg/kg/day) or a control solution (drugs mixed with the food). In experiment 1, treatments lasted 26 days and feeding patterns were measured on day 21. In experiment 2, treatments lasted for 46 days, and an oral glucose tolerance test (OGTT) was realised on day 31. At the end of both experiments, plasma parameters and body composition were analysed. RESULTS: In experiment 1, olanzapine-treated animals showed increased meal number, decreased ingestion rate, meal size and inter-meal interval, and no change in total food intake. Plasma glucose, OGTT and body composition were not altered. In experiment 2, after 31 days of treatment, fasting blood glucose was increased and OGTT indicated an insulin resistance. After 46 days of treatment, hyperglycaemia was aggravated (compared to 31 days), and adiposity was increased in olanzapine-treated animals. In both experiments, the haloperidol-treated rats did not differ from the control ones. CONCLUSION: Chronic olanzapine treatment produces changes in feeding patterns, in a way consistent with an increased incentive drive to eat. As a whole, the results raise the hypothesis that long-term alteration of feeding pattern by olanzapine may predispose to disturbances in the regulation of energy metabolism.
Authors: Donna A Wirshing; Jennifer A Boyd; Laura R Meng; Jacob S Ballon; Stephen R Marder; William C Wirshing Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: Julie Minet-Ringuet; Patrick C Even; Benjamin Guesdon; Daniel Tomé; Renaud de Beaurepaire Journal: Behav Brain Res Date: 2005-09-08 Impact factor: 3.332
Authors: James L Roerig; James E Mitchell; Martina de Zwaan; Ross D Crosby; Blake A Gosnell; Kristine J Steffen; Stephen A Wonderlich Journal: J Clin Psychopharmacol Date: 2005-10 Impact factor: 3.153
Authors: Trino Baptista; Emma Araujo de Baptista; Josee Lalonde; Julie Plamondon; N M K Ng Ying Kin; Serge Beaulieu; Rhida Joober; Denis Richard Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2004-12 Impact factor: 5.067
Authors: M J Fell; N Anjum; K Dickinson; K M Marshall; L M Peltola; S Vickers; S Cheetham; J C Neill Journal: Psychopharmacology (Berl) Date: 2007-06-21 Impact factor: 4.415
Authors: Kieran J Davey; Siobhain M O'Mahony; Harriet Schellekens; Orla O'Sullivan; John Bienenstock; Paul D Cotter; Timothy G Dinan; John F Cryan Journal: Psychopharmacology (Berl) Date: 2012-01-11 Impact factor: 4.530
Authors: Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn Journal: Psychopharmacology (Berl) Date: 2016-06-01 Impact factor: 4.530
Authors: Claire Wu; Jessica Yuen; Heidi N Boyda; Ric M Procyshyn; Cathy K Wang; Yahya I Asiri; Catherine C Y Pang; William G Honer; Alasdair M Barr Journal: PLoS One Date: 2014-09-25 Impact factor: 3.240
Authors: Heidi N Boyda; Ric M Procyshyn; Catherine C Y Pang; Erin Hawkes; Daniel Wong; Chen Helen Jin; William G Honer; Alasdair M Barr Journal: PLoS One Date: 2013-01-09 Impact factor: 3.240
Authors: K J Davey; P D Cotter; O O'Sullivan; F Crispie; T G Dinan; J F Cryan; S M O'Mahony Journal: Transl Psychiatry Date: 2013-10-01 Impact factor: 6.222